Catalyst Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Catalyst Pharmaceuticals has a total shareholder equity of $387.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $470.1M and $82.2M respectively. Catalyst Pharmaceuticals's EBIT is $86.8M making its interest coverage ratio -18.6. It has cash and short-term investments of $137.6M.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | -18.6x |
Cash | US$137.64m |
Equity | US$387.88m |
Total liabilities | US$82.23m |
Total assets | US$470.11m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CN2's short term assets ($219.3M) exceed its short term liabilities ($76.1M).
Long Term Liabilities: CN2's short term assets ($219.3M) exceed its long term liabilities ($6.2M).
Debt to Equity History and Analysis
Debt Level: CN2 is debt free.
Reducing Debt: CN2 has not had any debt for past 5 years.
Debt Coverage: CN2 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CN2 has no debt, therefore coverage of interest payments is not a concern.